A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2007-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is being conducted to provide initial safety, tolerability, PK and PD data that will allow further studies with darapladib in Japanese patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-

NCT00622830

Atherosclerosis

COMPLETED PHASE1

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

NCT00743860

Atherosclerosis

COMPLETED PHASE1

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723

Atherosclerosis

COMPLETED PHASE1

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

NCT01154114

Atherosclerosis

COMPLETED PHASE1

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients

NCT00734032

Atherosclerosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Darapladib (SB480848)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Japanese males, 20-64 years of age, inclusive
* Body weight \>50Kg
* Body Mass Index (BMI): 18-28
* Subjects must have lived outside of Japan no more than 10 years
* Non-smoker or smokes fewer than 10 cigarettes/day

Exclusion Criteria

* History of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses
* History of sensitivity to heparin or heparin-induced thrombocytopenia
* History of alcohol/drug abuse or dependence within 12 months of the study
* Positive syphilis, HIV antibody, Hepatitis B, Hepatitis C
* History of cholecystectomy or biliary tract disease or history of liver disease
* Participation in a clinical study within 30 days prior to first dose
* Subject has been exposed to more than 4 chemical entities within 12 months
* Positive urine drug and alcohol at screening
* Subject has any medical history or clinically relevant abnormality that would make the subject ineligible for inclusion due to safety reasons.

Minimum Eligible Age

20 Years

Maximum Eligible Age

64 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Honolulu, Hawaii, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.